Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

Dexamethasone 17daratumumab 10Bortezomib 10Lenalidomide 6pomalidomide 4carfilzomib 4isatuximab 3trametinib 2selinexor 2dabrafenib 2Thalidomide 2Prednisone 2Melphalan 2ulixertinib 1trastuzumab biosimilar HLX02 1talquetamab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1montelukast 1melflufen 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1darlin protein, Dictyostelium 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × pomalidomide × Plasma cell × Clear all
NCT05083169 2026-05-08

MajesTEC-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
587 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
240 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Sanofi

Phase 3 Completed
307 enrolled 32 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡